Reaching New Heights 'Moving Together Against Breast Cancer'; Lilly, Komen Italia Onlus and Kristin Scott Thomas Address Importa

    Eli Lilly and Company

Eli Lilly and Company, together with Komen Italia Onlus and
Academy award nominee, Kristin Scott Thomas, join international breast
cancer experts to highlight progress and emphasize the value of
partnerships in the fight against the disease in conjunction with a
scientific congress, Perspectives in Breast Cancer, in Monaco today.
¶   Speakers will discuss how maximizing partnerships, including
combination chemotherapies, may assist in fulfilling the European
Parliament's resolution, which calls upon Member States to create the
conditions necessary for a 25 percent reduction in the average breast
cancer mortality rate by 2008.
¶   "So many women's lives are affected by breast cancer. It is
imperative that we take action and make resources available that help
women in their struggle to overcome this disease," said Kristin Scott
Thomas, celebrity host of the Pas de Deux program. "True partnerships
between patients, physicians, loved ones and carers, can significantly
impact a breast cancer patient's experience, both clinically and
emotionally."
¶   Pas de Deux - a French ballet term meaning "step for two" - allows
partners to achieve more, reaching heights together not attainable by
one.
¶   Partnerships and information exchange have a direct impact on a
breast cancer patient's experience, treatment decisions and outcomes.
Lilly, together with Komen, is announcing today their new partnership
in the development of the Pas de Deux Patient Portal. This online
resource, to be housed on Komen's website, will offer women the
opportunity to build valuable partnerships with other patients and
physicians while exchanging information, experiences and
encouragement. The portal will also offer patients access to
information on treatment options and clinical trial research - central
components to furthering advances in breast cancer care.
¶   "Breast cancer is a life-threatening disease, but through recent
advances in research, education and advocacy it is becoming more
manageable with the promise of more positive outcomes," said Professor
Riccardo Masetti, president, Komen Italia Onlus. "Partnerships are an
essential part of helping women with breast cancer and their
physicians create bridges to attain superior therapeutic goals. It is
imperative to provide women with effective, manageable treatments and
the resources to make the best treatment decisions."
¶   Forming positive partnerships also involves having access to new
therapeutic choices that meet patient need. New combination
chemotherapies provide metastatic breast cancer patients with
additional weapons in fighting their disease.
¶   "Combination chemotherapy is emerging as an important treatment
option for women with metastatic breast cancer. A few new combination
therapies show efficacy advantages in breast cancer while also
offering manageable side effect profiles," said Professor Christoph C.
Zielinski, University Hospital Vienna, Austria. "Combination regimes
are shaping the future of cancer care, and will continue to be the
focus of research and development in oncology. These important
combinations may help researchers transform cancer in the future from
a fatal disease, to one that is chronic and manageable."
¶   Perspectives in Breast Cancer congress is convened by Matti S.
Aapro, M.D., Institut Multidiciplinaire d'Oncologie, Genolier,
Switzerland and Veronique Dieras, M.D., Institut Curie, Paris, France.

¶   Lilly Oncology

¶   Lilly is at the forefront in this era of cancer discovery. Already
recognized globally as a leader in neuroscience and diabetes, Lilly
has made significant strides in building its oncology presence in
recent years with an approved therapy and pipeline compounds that show
potential for treating a wide range of tumors. Lilly is emerging as a
leader in the search for solutions to some of the most devastating
cancers known to mankind.
¶   Lilly, a leading innovation-driven corporation is developing a
growing portfolio of best-in-class pharmaceutical products by applying
the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers - through medicines and
information - for some of the world's most urgent medical needs.

¶   About Komen Italia Onlus

¶   "Komen Italia Onlus" is the Italian affiliate of the Susan G.
Komen Breast Cancer Foundation of Dallas, the largest private funded
organization solely dedicated to the cure of breast cancer in the US.
This non-profit organization was started in 2000, thanks to a
continuous cooperation with the Catholic University of Rome, and the
combined efforts of a task force of medical experts, breast cancer
survivors, and representatives of women associations.

¶   About Kristin Scott Thomas

¶   Born in Redruth, Cornwall, Kristin's major cinematic debut came in
Prince's Under the Cherry Moon in 1986. Since then Kristin has held a
steady series of roles in films and television including, starring as
Fiona in Four Weddings and a Funeral in 1994 -- for which she was
awarded a BAFTA and an Evening Standard Award for Best Actress, as
Sarah Davies in Mission: Impossible (1996) and as Katharine Clifton --
her Oscar-nominated role in The English Patient (1996). Kristin has
also starred opposite Robert Redford in The Horse Whisperer (1998) and
Harrison Ford in Random Hearts (1999). In 2001, Kristin starred as
Sylvia McCordle in Gosford Park. Currently she is filming Arsene
Lupin, a French film directed by Jean-Paul Salome. She presently lives
with her husband and their three children in Paris.